Does TALAZOPARIB Cause Neoplasm progression? 169 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 169 reports of Neoplasm progression have been filed in association with TALAZOPARIB (Talzenna). This represents 11.4% of all adverse event reports for TALAZOPARIB.
169
Reports of Neoplasm progression with TALAZOPARIB
11.4%
of all TALAZOPARIB reports
54
Deaths
37
Hospitalizations
How Dangerous Is Neoplasm progression From TALAZOPARIB?
Of the 169 reports, 54 (32.0%) resulted in death, 37 (21.9%) required hospitalization, and 9 (5.3%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALAZOPARIB. However, 169 reports have been filed with the FAERS database.
What Other Side Effects Does TALAZOPARIB Cause?
Anaemia (219)
Death (142)
Off label use (78)
Thrombocytopenia (78)
Fatigue (77)
Platelet count decreased (68)
Haemoglobin decreased (65)
Febrile neutropenia (60)
Pancytopenia (60)
Nausea (53)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which TALAZOPARIB Alternatives Have Lower Neoplasm progression Risk?
TALAZOPARIB vs TALC
TALAZOPARIB vs TALIGLUCERASE ALFA
TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC
TALAZOPARIB vs TALQUETAMAB
TALAZOPARIB vs TALQUETAMAB-TGVS